Turner Syndrome (45,X)
Sex Chromosome Aneuploidy Syndrome (Monosomy X)
Primary risk age: Infancy through Adolescence (Often diagnosed in infancy due to physical features, or in adolescence due to short stature/amenorrhea; affects girls)
- Urgency
- Moderate
- Typical age
- Infancy through Adolescence (Often diagnosed in infancy due to physical features, or in adolescence due to short stature/amenorrhea; affects girls)
- Body system
- Genetic & Chromosomal
Typical course: This is a lifelong chromosomal genetic condition requiring active management during growth and transition to adulthood.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Sex Chromosome Aneuploidy Syndrome (Monosomy X)
Pathophysiology (Development Path)
The lack of the second sex chromosome leads to the accelerated loss of oocytes in fetal ovaries, resulting in "streak ovaries" and estrogen deficiency. A deficiency in the SHOX gene on the X chromosome causes short stature and skeletal anomalies.
Primary Causes & Etiology
Loss of one of the sex chromosomes (X chromosome) during gametogenesis or early mitotic division, resulting in a 45,X karyotype (or mosaicism).
2. Symptom Continuum
- Early Onset Signs
Lymphedema (swelling) of the hands and feet at birth, a webbed neck (cystic hygroma remnant), a low posterior hairline, and a broad chest with widely spaced nipples.
- Progressive Phase
Progressive growth failure leading to short stature (typically apparent by age 5). Normal intelligence but potential difficulty with spatial processing.
- Severe Indicators
Primary amenorrhea (failure to start periods) and lack of breast development due to ovarian dysgenesis (gonadal streak). Congenital heart anomalies, particularly Coarctation of the Aorta and bicuspid aortic valve.
3. Clinical Verification
Confirmed by chromosomal karyotype analysis showing a 45,X configuration or mosaic variant.
4. Care & Elements Plan
Primary Care Treatment Plan
Initiate recombinant growth hormone therapy in early childhood to maximize adult height. Begin estrogen replacement therapy around age 11-12 to induce puberty, breast development, and support bone health, transitioning to cyclic progesterone.
Home Support Elements
Monitor growth closely using specialized Turner syndrome growth charts. Support self-esteem and address learning concerns related to spatial skills.
Generic Active Ingredients (No Brands)
- Somatropin (generic recombinant growth hormone active ingredient)
- Estradiol (generic active estrogen replacement ingredient)
- Progesterone (generic active progestin hormone).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Seek evaluation if a girl has unexplained short stature, lack of pubertal development, or if newborn features like webbed neck or swollen feet were present.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
No preventative measures exist, as this is a random genetic nondisjunction event.
Immunization Context
No specific immunizations are associated with this chromosomal condition.
7. Timelines & Outlook
Active Timeline
This is a lifelong chromosomal genetic condition requiring active management during growth and transition to adulthood.
Expected Prognosis
Good. With growth hormone and estrogen therapy, girls can achieve normal height ranges and lead fulfilling lives, though fertility is generally absent (except via assisted reproduction).
Potential Untreated Complications
Coarctation of the aorta, aortic dissection, hypertension, horseshoe kidney, hypothyroidism, osteoporosis, and hearing loss.
